IFNA1 and infection: Therefore, while IFN therapy may not confer benefits to all patients, it holds potential utility for specific patient subsets, including those who receive early treatment during infection and individuals exhibiting markedly low IFN responses (Feld et al., 2021; Monk et al., 2021).